Inhibition of human B-cell development into plasmablasts by histone deacetylase inhibitor valproic acid

Journal of Allergy and Clinical Immunology

Volumn 131, Issue 6, 2013, Pages 1695-1699.e9

  Kienzler, Anne Kathrin ^a,b   Rizzi, Marta ^a   Reith, Maike ^a   Nutt, Stephen L ^c   Eibel, Hermann ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD27 ANTIGEN; CD38 ANTIGEN; CD40 LIGAND; HISTONE DEACETYLASE; INTERLEUKIN 21; VALPROIC ACID;

B LYMPHOCYTE ACTIVATION; B LYMPHOCYTE DIFFERENTIATION; CELL MATURATION; CONCENTRATION RESPONSE; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN PRODUCTION; LETTER; MEMORY CELL; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84878574917     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2013.01.018     Document Type: Article

References (23)

1. M. Gottlicher, S. Minucci, P. Zhu, O.H. Kramer, A. Schimpf, and S. Giavara Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells EMBO J 20 2001 6969 6978
2. M. Kaiser, I. Zavrski, J. Sterz, C. Jakob, C. Fleissner, and P. Kloetzel The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma Haematologica 91 2006 248 251
3. A. Nencioni, J. Beck, D. Werth, F. Grunebach, F. Patrone, and A. Ballestrero Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity Clin Cancer Res 13 2007 3933 3941
4. T. Yamaguchi, F. Cubizolles, Y. Zhang, N. Reichert, H. Kohler, and C. Seiser Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression Genes Dev 24 2010 455 469
5. D.T. Avery, E.K. Deenick, C.S. Ma, S. Suryani, N. Simpson, and G.Y. Chew B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans J Exp Med 207 2010 155 171
6. P.M. Callenbach, C.M. Jol-Van Der Zijde, A.T. Geerts, W.F. Arts, C.A. Van Donselaar, and A.C. Peters Immunoglobulins in children with epilepsy: the Dutch Study of Epilepsy in Childhood Clin Exp Immunol 132 2003 144 151
7. T.H. Eom, H.S. Lee, P.S. Jang, and Y.H. Kim Valproate-induced panhypogammaglobulinemia Neurol Sci 2012 [Epub ahead of print]
8. P. Garzon, S. Gonzalez-Cornejo, S. Roman-Maldonado, and A. Navarro-Ruiz Valproic acid and phenytoin effects on serum proteins and immunoglobulins of epileptic patients Gen Pharmacol 16 1985 411 413
9. J. Vojinovic, N. Damjanov, C. D'Urzo, A. Furlan, G. Susic, and S. Pasic Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis Arthritis Rheum 63 2011 1452 1458
10. G. Cambridge, M.J. Leandro, M. Teodorescu, J. Manson, A. Rahman, and D.A. Isenberg B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles Arthritis Rheum 54 2006 3612 3622
11. J. Lv, C. Du, W. Wei, Z. Wu, G. Zhao, and Z. Li The antiepileptic drug valproic acid restores T cell homeostasis and ameliorates pathogenesis of experimental autoimmune encephalomyelitis J Biol Chem l287 2012 28656 28665
12. S.J. Saouaf, B. Li, G. Zhang, Y. Shen, N. Furuuchi, and W.W. Hancock Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis Exp Mol Pathol 87 2009 99 104
13. Z. Zhang, Z.Y. Zhang, U. Fauser, and H.J. Schluesener Valproic acid attenuates inflammation in experimental autoimmune neuritis Cell Mol Life Sci 65 2008 4055 4065
14. S. Skov, K. Rieneck, L.F. Bovin, K. Skak, S. Tomra, and B.K. Michelsen Histone deacetylase inhibitors: a new class of immunosuppressors targeting a novel signal pathway essential for CD154 expression Blood 101 2003 1430 1438
15. R. Grausenburger, I. Bilic, N. Boucheron, G. Zupkovitz, L. El-Housseiny, and R. Tschismarov Conditional deletion of histone deacetylase 1 in T cells leads to enhanced airway inflammation and increased Th2 cytokine production J Immunol 185 2010 3489 3497
16. T. Akimova, G. Ge, T. Golovina, T. Mikheeva, L. Wang, and J.L. Riley Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs Clin Immunol 136 2010 348 363
17. L.R. Shiow, D.B. Rosen, N. Brdickova, Y. Xu, J. An, and L.L. Lanier CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs Nature 440 2006 540 544
18. N.L. Bernasconi, E. Traggiai, and A. Lanzavecchia Maintenance of serological memory by polyclonal activation of human memory B cells Science 298 2002 2199 2202
19. K.G. Smith, T.D. Hewitson, G.J. Nossal, and D.M. Tarlinton The phenotype and fate of the antibody-forming cells of the splenic foci Eur J Immunol 26 1996 444 448
20. M. Muramatsu, K. Kinoshita, S. Fagarasan, S. Yamada, Y. Shinkai, and T. Honjo Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme Cell 102 2000 553 563
21. P.D. Hodgkin, J.H. Lee, and A.B. Lyons B cell differentiation and isotype switching is related to division cycle number J Exp Med 184 1996 277 281
22. M.J. Shlomchik, and F. Weisel Germinal center selection and the development of memory B and plasma cells Immunol Rev 247 2012 52 63
23. K. Warnatz, U. Salzer, M. Rizzi, B. Fischer, S. Gutenberger, and J. Bohm B-cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans Proc Natl Acad Sci U S A 106 2009 13945 13950